Stemedica announced today the completion of enrollment and treatment of patients in a Phase I study with Stemedica’s lead product Stemedyne-MSC. These specially formulated ischemic adult allogeneic mesenchymal stem cells have been manufactured at Stemedica’s cGMP compliant facility and have been successfully used to treat patients in an ischemic stroke study “A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability and Preliminary Treatment Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects with Ischemic Stroke.”
Stemedica announced today they have entered into a Global Distribution Agreement with Life Technologies Corporation. Under the terms of this agreement, Life Technologies will exclusively offer Stemedica’s ischemic tolerant allogeneic adult mesenchymal stem cells (itMSCs) and neural stem cells (itNSCs) for sale worldwide to research, academic institutions and corporations both in the United States and internationally.
DRIVEN BY 30 YEARS OF STEM CELL RESEARCH & SCIENTIFIC ADVANCEMENT
Transforming Medicine for the 21st Century
Stemedica Cell Technologies, Inc., is transforming regenerative medicine through the development and manufacturing of adult ischemic-tolerant stem cell products and biological compounds. Our technology has led us to breakthroughs that are changing medicine and improving life globally. As one of the few companies licensed and approved for clinical grade manufacturing and trial applications by regulatory agencies worldwide, our focus is on producing the best-in-class products available today.
Watch a short informative video about our company and the unique technological advantages of our proprietary adult stem cells.
NOTED CARDIOLOGIST ROBERT WILENSKY TO JOIN STEMEDICA CARDIOLOGY DIVISION SCIENTIFIC & MEDICAL ADVISORY BOARD
Stemedica announced today that Robert L. Wilensky, MD, Professor of Medicine and Director of Interventional Cardiology Research at the University of Pennsylvania has agreed to join the Scientific and Medical Advisory Board for Stemedica’s Cardiology Division.
The Miracle of Stem Cells Book
Stemedica has recently
authored one of the most comprehensive and well researched books on adult allogeneic
The 288 pages of this full color hardback book details over 100 years of the history of stem cells and includes over 360 scientific references.
Further information >>